Immuron Announces A New Research Agreement With The Naval Medical Research Command And The Walter Reed Army Institute Of Research, Funded By U.S. Department Of Defense Subaward

As previously announced on August 16, 2024, the Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting Campylobacter jejuni and Shigella sonnei. Under a recently executed collaborative research agreement with the Henry M. Jackson Foundation, new vaccine preparations against these pathogens have been developed and formulated at the military research institutes and subsequently provided to Immuron. Utilizing its proprietary technology platform, Immuron will produce two hyper-immune bovine colostrum products for pre-clinical evaluation, with the objective of advancing a combined colostrum-based therapeutic specifically designed for the US military.

The company also advises that the Uniformed Services University topline results from its clinical trial evaluating the effectiveness of enterotoxigenic E. coli (ETEC) hyperimmune bovine colostrum in maintaining gut health during deployment and travel are anticipated to be announced at the end of next week. As disclosed on October 31, 2025, the Uniformed Services University completed the P2TD study (NCT04605783), in which IMM-124E—the active ingredient in Travelan®—was delivered in 600 mg powder sachets and administered twice daily in a randomized, placebo-controlled trial.